UK markets closed

RELMADA THERAPEUT.DL-,001 (4E2.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
3.4000+0.1600 (+4.94%)
As of 08:04AM CEST. Market open.
Full screen
Previous close3.2400
Open3.4000
Bid3.4600 x N/A
Ask3.5400 x N/A
Day's range3.4000 - 3.4000
52-week range3.4000 - 3.4000
Volume50
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • PR Newswire

    Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

    Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2023. The Company will host a conference call today, Tuesday, March 19, at 4:30 PM Eastern Time/1:30 PM Pacific Time.

  • PR Newswire

    Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024

    Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2023 after the market close on Tuesday, March 19, 2024. The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Tuesday, March 19, 2024.

  • PR Newswire

    Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

    Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer will participate in the Leerink Partners Global Biopharma Conference in one-on-one investor meetings, taking place March 11-13, 2024, in Miami Beach, Florida. Please see below for additional details about the event and how to request a one-on-one meeting wit